title: [New developments in Waldenström's macroglobulinemia].
abstract: Waldenström's Macroglobulinemia (WM) is a rare subtype of B-cell lymphoma with mostly indolent course. Until now the backbone of therapy is still Rituximab / Chemotherapy. In recent years whole genome sequencing has revealed a number of genetic mutations, among them mutations of the MYD88 gene which occurs in over 90 % of patients and helps to validate diagnosis of WM in difficult cases. With the introduction of ibrutinib, an oral bruton-tyrosine-kinase inhibitor, an effective chemotherapy-free treatment option is available.
authors: Alexander
authors: A
authors: Grunenberg
authors: Christian
authors: C
authors: Buske
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D009154:Mutation; D000069283:Rituximab / Q000627:therapeutic use; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D000069283:Rituximab